| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:b78e80b6dab8298a","evidence_event_ids":["evt_35cd0e790311"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","company":"Virax Biolabs Group Ltd","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","article_chars":2553,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2bc3e3a5b90d0592","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","content_type":"text/plain","enriched_at":"2026-04-11T04:39:08.487112+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"6-K","final_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt","source_event_id":"evt_35cd0e790311","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"9b84afffe8d40d5d","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2025-12-04","2025-12-03","2026-04-10","2026-04-11"],"entities":[{"asset_class":"equity","name":"Virax Biolabs Group Limited","relevance":"high","symbol":"VRAX","type":"issuer"},{"asset_class":"unknown","name":"Purchaser (accredited investor)","relevance":"medium","symbol":"","type":"counterparty"}],"event_type":"listing","information_gaps":["What specifically changed versus the prior known state is only partially inferable from the text: the filing states that as of April 10, 2026 all pre-funded warrants had been exercised, but it does not provide the prior (pre-exercise) warrant exercise status or prior share count in the provided excerpt.","The excerpt does not include the referenced registration statement details (e.g., filing/effectiveness date) beyond stating that preferred options are tied to its effectiveness.","No placement agent fees or offering expenses amounts are disclosed in the provided text."],"key_facts":["The company filed a Form 6-K for the month of April 2026.","The filing relates to an unregistered sale of equity securities disclosed previously on a Form 6-K filed December 4, 2025.","On December 3, 2025, Virax entered into a securities purchase agreement with an accredited investor for a private placement.","The company received gross proceeds of $5,000,000 before deducting placement agent fees and other offering expenses.","The offering included pre-funded warrants to purchase 12,500,000 ordinary shares and preferred investment options to purchase up to 12,500,000 ordinary shares.","Pre-funded warrants: exercise price $0.0001 per share, exercisable commencing on issuance date, and do not expire.","Preferred options: exercise price $0.40 per ordinary share, exercisable immediately upon issuance for a period of five years from the date of effectiveness of a referenced registration statement.","As of April 10, 2026, all pre-funded warrants had been exercised.","As of April 10, 2026, total ordinary shares outstanding were 19,923,432."],"numeric_claims":[{"label":"gross proceeds (USD)","value":"5,000,000"},{"label":"pre-funded warrants shares","value":"12,500,000"},{"label":"preferred options shares (up to)","value":"12,500,000"},{"label":"pre-funded warrant purchase price (USD per unit)","value":"0.3999"},{"label":"pre-funded warrant exercise price (USD per share)","value":"0.0001"},{"label":"preferred option exercise price (USD per share)","value":"0.40"},{"label":"preferred options exercisable period","value":"5 years"},{"label":"pre-funded warrants exercised as of","value":"2026-04-10"},{"label":"total ordinary shares outstanding","value":"19,923,432"}],"primary_claim":"As of April 10, 2026, all pre-funded warrants issued in the December 3, 2025 private placement had been exercised, and total ordinary shares outstanding were 19,923,432.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Virax Biolabs Group Ltd filed a Form 6-K in April 2026 disclosing the status of its previously announced unregistered private placement. As of April 10, 2026, all pre-funded warrants from that offering had been exercised.","topics":["SEC filing","Form 6-K","unregistered sale of equity securities","private placement","pre-funded warrants","ordinary shares outstanding"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 Virax Biolabs Group Ltd \u00b7 Filed 20260410","ticker":"VRAX","tickers":["VRAX"],"title":"VRAX filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/1885827/0001193125-26-151292.txt"}}... |